CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that a poster relating to the Company’s development of its comprehensive patient reported outcome (PRO) measures used to assess symptom severity and symptom change in patients with hereditary angioedema (HAE) was presented this weekend at the 2007 Annual Meeting of the American College of Allergy, Asthma & Immunology being held in Dallas, TX. HAE is a rare genetic disease characterized by episodes of acute swelling and inflammation. Dyax is currently conducting a second Phase 3 trial (EDEMA4) in this indication.
